Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Synergistic enhancement of resistance to cisplatin in human bladder cancer cells by overexpression of mutant-type p53 and Bcl-2.

The Journal of urology - 1 Dec 1999

Miyake H, Hara I, Yamanaka K, Arakawa S, Kamidono S

Abstract excerpt

PURPOSE: The objective of this study was to characterize the effect of mutant-type p53 and Bcl-2 expression on the sensitivity to cisplatin in a human bladder cancer cell line both in vitro and in vivo. MATERIALS AND METHODS: We transfected mutant-type p53 cDNA, Bcl-2 cDNA, or both cDNAs into KoTCC-1, a human bladder cancer cell line that does not express mutant-type p53 or Bcl-2 protein. The effects of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cisplatin
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, bcl-2

Share to Genes, p53

Share to Mice, Nude

Share to Tumor Cells, Cultured

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 10569615
DOI: 10.1016/S0022-5347(05)68155-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Synergistic enhancement of resistance to cisplatin in human bladder cancer cells by overexpression of mutant-type p53 and Bcl-2.PMID 10569615Read ↗

The Histone Deacetylase Inhibitor Trichostatin A Synergistically Resensitizes a Cisplatin Resistant Human Bladder Cancer Cell LineSemantic proximity Read ↗

Exogenous mutant p53 DNA enhanced cisplatin-induced apoptosis in TSGH-8301 human bladder cancer cells.Semantic proximity Read ↗

Overexpression of Bcl-2 enhances metastatic potential of human bladder cancer cells.Semantic proximity Read ↗

Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine.Semantic proximity Read ↗

Various forms of mutant p53 confer sensitivity to cisplatin and doxorubicin in bladder cancer cells.Semantic proximity Read ↗

Enhancement of chemosensitivity in human bladder cancer cells by adenoviral-mediated p53 gene transfer.Semantic proximity Read ↗

Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway.Semantic proximity Read ↗

Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responsesSemantic proximity Read ↗

MVAC chemotherapy-induced apoptosis and p53 alterations in the rat model of bladder cancer.Semantic proximity Read ↗

Radiation induces p53-dependent cell apoptosis in bladder cancer cells with wild-type- p53 but not in p53-mutated bladder cancer cells.Semantic proximity Read ↗

Synthetic Bax-Anti Bcl2 combination module actuated by super artificial hTERT promoter selectively inhibits malignant phenotypes of bladder cancer.Semantic proximity Read ↗

Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatinSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.